QED Pharmaceutical Services Picks SAS Clinical Data Integration to Help Clients Implement CDISC Standards
QED Pharmaceutical Services has licensed SAS® Clinical Data Integration to enable its drug development clients to more easily form partnerships with key biopharmaceutical companies. SAS offers a comprehensive portfolio of life sciences software solutions for pharmaceutical, biotechnology and medical device companies.
“The availability of SAS Clinical Data Integration has made it possible for QED to efficiently implement complex data standards such as the CDISC standards,” said Dr. Ramana Kuchibhatla, QED founder. “This allows us to help our clients - predominantly small and sometimes virtual biopharmaceutical companies - achieve important milestones despite their size. Compliance with the latest CDISC standards makes growing drug developers like our clients very attractive partners to large pharma companies that are looking to in-license successful drug development programs. ”
QED also uses other SAS products including SAS® Enterprise Business Intelligence. With the knowledge base created by these systems, QED can offer cost-effective services for its clients. “It’s as if we have designed an efficient mechanical engine, and now, with little modification for each clinical trial, we can crank out CDISC-compliant data and get our clients’ datasets output in regulatory submission-ready formats,” said Kuchibhatla.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
